Opko Health, Inc. (OPK) Downgraded by Zacks Investment Research
Opko Health, Inc. (NASDAQ:OPK) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “
Several other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of Opko Health in a research note on Thursday, August 17th. They issued an “overweight” rating and a $20.00 target price for the company. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $19.50 target price on shares of Opko Health in a research note on Friday, June 16th. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. J P Morgan Chase & Co cut shares of Opko Health from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $12.00 to $7.00 in a research note on Thursday, September 14th. Finally, Barrington Research raised their price target on Opko Health to $11.00 and gave the company an “outperform” rating in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $13.97.
Shares of Opko Health (NASDAQ OPK) traded up 1.02% during mid-day trading on Wednesday, hitting $6.95. 2,698,792 shares of the stock were exchanged. The company’s market capitalization is $3.89 billion. Opko Health has a 12-month low of $5.85 and a 12-month high of $12.15. The firm has a 50-day moving average price of $6.56 and a 200 day moving average price of $6.70.
Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The business had revenue of $314.20 million during the quarter, compared to analysts’ expectations of $322.64 million. During the same period last year, the business earned $0.02 earnings per share. The firm’s revenue was down 12.0% on a year-over-year basis. On average, equities research analysts expect that Opko Health will post ($0.20) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Opko Health, Inc. (OPK) Downgraded by Zacks Investment Research” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/15/opko-health-inc-opk-downgraded-by-zacks-investment-research-2.html.
In other news, CEO Phillip Md Et Al Frost bought 45,000 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was bought at an average price of $6.42 per share, with a total value of $288,900.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $19,702,665.42. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have acquired a total of 925,800 shares of company stock valued at $5,667,905 in the last ninety days. Insiders own 40.19% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Eqis Capital Management Inc. lifted its holdings in shares of Opko Health by 28.5% during the third quarter. Eqis Capital Management Inc. now owns 51,135 shares of the biotechnology company’s stock worth $351,000 after buying an additional 11,354 shares in the last quarter. Piedmont Investment Advisors LLC raised its stake in Opko Health by 43.4% in the second quarter. Piedmont Investment Advisors LLC now owns 230,643 shares of the biotechnology company’s stock valued at $1,518,000 after purchasing an additional 69,818 shares in the last quarter. Psagot Investment House Ltd. raised its stake in Opko Health by 20.0% in the second quarter. Psagot Investment House Ltd. now owns 22,862 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 3,806 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Opko Health by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 1,657 shares in the last quarter. Finally, State Street Corp raised its stake in Opko Health by 3.9% in the second quarter. State Street Corp now owns 11,348,763 shares of the biotechnology company’s stock valued at $74,671,000 after purchasing an additional 422,203 shares in the last quarter. 22.46% of the stock is owned by institutional investors.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.